Benefits in doubt as 50% of new drugs fail to impress in Germany
This article was originally published in SRA
Executive Summary
Many pharmaceutical companies are having a hard time demonstrating to Germany's health technology assessment authorities that their medicinal products offer sizeable additional benefits, according to research by Scrip Regulatory Affairs' sister publication Scrip Intelligence. The table below shows which medicines have come out on top and which have struggled.